Paul N Mainwaring

Paul N Mainwaring

UNVERIFIED PROFILE

Are you Paul N Mainwaring?   Register this Author

Register author
Paul N Mainwaring

Paul N Mainwaring

Publications by authors named "Paul N Mainwaring"

Are you Paul N Mainwaring?   Register this Author

16Publications

872Reads

18Profile Views

Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management.

Nat Rev Urol 2019 May;16(5):302-317

Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41585-019-0178-2
Publisher Site
http://dx.doi.org/10.1038/s41585-019-0178-2DOI Listing
May 2019

Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction.

ACS Nano 2018 08 26;12(8):8362-8371. Epub 2018 Jul 26.

Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology , University of Queensland , Brisbane , QLD 4072 , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsnano.8b03698DOI Listing
August 2018

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

N Engl J Med 2018 Apr 8;378(15):1408-1418. Epub 2018 Feb 8.

From the Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (M.R.S.); Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal (F.S.); Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London (S.C.); Georges Pompidou Hospital, Paris (S.O.); University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (B.A.H.); Veterans Affairs Portland Health Care System, Portland, and Knight Cancer Institute, Oregon Health and Science University, Portland (J.N.G.); Spanish National Cancer Research Center, Madrid, and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Malaga, Malaga - both in Spain (D.O.); Centre for Personalised Nanomedicine, University of Queensland, Brisbane, Australia (P.N.M.); St. Mary's Hospital of Catholic University, Seoul, South Korea (J.Y.L.); Yokohama City University Medical Center, Yokohama, Japan (H.U.); Janssen Research and Development, Los Angeles (A.L.-G., G.C.T., B.M.E., Y.S., Y.C.P., W.R.R., M.K.Y.); and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco (E.J.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715546DOI Listing
April 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
March 2018

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

J Clin Oncol 2017 Oct 28;35(28):3189-3197. Epub 2017 Jul 28.

Stéphane Oudard, Georges Pompidou European Hospital, Rene Descartes University; Mustapha Chadjaa; Sanofi, Paris; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Antoine Thiery-Vuillemin, Centre Hospitalier Universitaire Minjoz Besançon, Besançon, France; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Steinbjørn Hansen, Odense University Hospital, Odense, Denmark; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Marie Hjälm-Eriksson, Karolinska University Hospital, Stockholm, Sweden; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Orazio Caffo, Santa Chiara Hospital, Trento, Italy; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; John Bernard, Sanofi, Cambridge, MA; Liji Shen, Sanofi, Bridgewater, NJ; and Oliver Sartor, Tulane Cancer Center, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1068DOI Listing
October 2017

Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.

Small 2016 Dec 26;12(45):6233-6242. Epub 2016 Sep 26.

Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, QLD, 4072, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.201602161DOI Listing
December 2016

A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA.

Sci Rep 2016 07 29;6:30722. Epub 2016 Jul 29.

Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, QLD 4072, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep30722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965811PMC
July 2016

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.

Asia Pac J Clin Oncol 2014 Sep 17;10(3):228-36. Epub 2014 Aug 17.

Sydney Adventist Hospital, University of Sydney, Wahroonga, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12264DOI Listing
September 2014

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Lung Cancer 2009 Aug 5;65(2):192-7. Epub 2009 May 5.

Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, The University of Auckland, 85 Park Rd, Grafton, Private Bag 92019, Auckland 1142, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.03.027DOI Listing
August 2009